Eterna Therapeutics (NASDAQ:ERNA) Stock Price Down 0.2% – Should You Sell?

Eterna Therapeutics Inc. (NASDAQ:ERNA)’s stock price fell 0.2% during mid-day trading on Monday . The company traded as low as $0.21 and last traded at $0.23. 444,010 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 2,812,653 shares. The stock had previously closed at $0.23.

Eterna Therapeutics Price Performance

The stock has a market capitalization of $14.22 million, a P/E ratio of -0.03 and a beta of 5.61. The stock’s fifty day moving average is $0.21 and its 200-day moving average is $0.32.

Institutional Investors Weigh In On Eterna Therapeutics

A hedge fund recently raised its stake in Eterna Therapeutics stock. Geode Capital Management LLC grew its holdings in Eterna Therapeutics Inc. (NASDAQ:ERNA) by 1,159.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 257,310 shares of the company’s stock after purchasing an additional 236,875 shares during the quarter. Geode Capital Management LLC owned about 4.76% of Eterna Therapeutics worth $76,000 as of its most recent filing with the SEC. 70.55% of the stock is owned by institutional investors and hedge funds.

About Eterna Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.